Caplin Point Laboratories Ltd's sterile product manufacturing subsidiary Caplin Steriles Ltd has received approval from the US Food and Drug Administration to market Thiamine Hydrochloride injection USP, the company said via an exchange filing.
The injection is a generic of Thiamine Hydrochloride injection of Fresenius Kabi USA LLC.
Thiamine Hydrochloride injection is used in the treatment of Thiamine, or Vitamin B1, deficiency and beriberi, a serious condition caused by a prolonged lack of Vitamin B1 in the body.
The Thiamine Hydrochloride injection had sales of $38 mln for the year ending September in the US, according to data by IQVIA.
'Sack Ajit Pawar': Netizens Demand Action Amid Row Over Phone Call Threatening IPS Officer Anjali Krishna
India firmly Rejects US Trade Adviser Peter Navarro’s Remarks On Brahmins Profiteering Over Russian Oil Deals
Mining Conglomerate Vedanta Beats Adani Group With ₹17,000 Crore Winning Bid For Acquisition Of Debt-Ridden Jaiprakash Associates
‘Deeply Appreciate And Fully Reciprocate…’: PM Modi’s 1st Reaction To US President Donald Trump’s ‘Will Always Be Friends’ Remark
Shares of Caplin Point Laboratories traded 0.8% higher at ₹671.15 on NSE, at 11:15 IST.
